Opinon: Off-Label Options and Compassionate Access to Phase II Drugs

With regard to the development of an efficacious treatment for ALS, we are still in its infancy. There is much more to be done—and much more quickly than we’ve seen.

Categories: Research News  |  Tags: ALS, ALS community, ALS research, ALS TDI, ALS Therapy Development Institute, clinical trial, compassionate access, Director of Neurology Clinical Trials Unit, FDA, fingolimod, Gilenya, Lou Gehrig’s disease, Massachusetts General Hospital, Merit Cudkowicz Director of Neurology Clinical Trials Unit, Merit Cudkowicz M.D., NEALS, Northeast ALS Consortium, off-label, Phase II clinical trial, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mouse model, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Steve Perrin, TDI 132  |  No comments